Canaccord lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $66 from $68 and keeps a Buy rating on the shares. The firm said they remain focused on the company’s CF program, which is now expected to readout data in mid-2025 vs 2Q25 previous. Canaccord have updated its model for 1Q25 results, and adjusted revenue recognition timing for Kostaive from 4Q26 to 1Q27.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Citi opens ’90-day Upside Catalyst Watch’ on Arcturus Therapeutics
- Strategic Shift to mRNA Therapeutics Positions Arcturus for Significant Upside
- Arcturus Therapeutics: Promising Vaccine Rollout and Cystic Fibrosis Treatment Drive Buy Rating
- Arcturus Therapeutics Reports Q1 2025 Financial Update
- Arcturus Therapeutics reports Q1 EPS (52c), consensus ($1.10)